Clinical Trial Update: Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of LN-145 autologous tumor-infiltrating lymphocytes for cervical carcinoma has been terminated with no further enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Carcinoma

Drugs mentioned

• LN-145 (autologous tumor-infiltrating lymphocytes)

Snippet

Sponsor: Iovance Biotherapeutics, Inc. | Conditions: Cervical Carcinoma | Phase 2 | Status: TERMINATED